AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2015
Jan 6, 2015
31580_dirs_2015-01-06_634dea3e-d440-47fc-a3aa-9b774e9a97e9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-01-02
Reporting Person: Biller Scott (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-02 | Common stock | M | 4500 | $0.4675 | Acquired | 47000 | Direct |
| 2015-01-02 | Common stock | S | 4500 | $110.08 | Disposed | 42500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-02 | Stock option (right to buy) | $0.4675 | M | 4500 | Disposed | 2020-12-06 | Common stock (4500) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $106.76 to $114.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This option was granted on December 7, 2010. The shares underlying this option vest as to 25% of the shares on September 20, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter.